CTNM
Contineum Therapeutics Inc. - Ordinary Shares - Class A

144
Mkt Cap
$343.27M
Volume
270,315.00
52W High
$15.25
52W Low
$3.35
PE Ratio
-5.16
CTNM Fundamentals
Price
$11.58
Prev Close
$11.63
Open
$11.61
50D MA
$11.32
Beta
0.42
Avg. Volume
188,721.42
EPS (Annual)
-$1.63
P/B
1.88
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Contineum Therapeutics (NASDAQ:CTNM) Stock Rating Lowered by Wall Street Zen
Wall Street Zen lowered shares of Contineum Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight analysts that are currently covering the stock...
MarketBeat·4d ago
News Placeholder
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering
Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire·4d ago
News Placeholder
Contineum Therapeutics Announces Proposed $75.0 Million Public Offering
Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire·4d ago
News Placeholder
Contineum Therapeutics (NASDAQ:CTNM) Price Target Cut to $22.00 by Analysts at Royal Bank Of Canada
Royal Bank Of Canada lowered their target price on Contineum Therapeutics from $25.00 to $22.00 and set an "outperform" rating for the company in a research note on Friday...
MarketBeat·23d ago
News Placeholder
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire·25d ago
News Placeholder
Contineum Therapeutics (NASDAQ:CTNM) Coverage Initiated at Leerink Partners
Leerink Partners initiated coverage on shares of Contineum Therapeutics in a report on Thursday. They issued an "outperform" rating and a $22.00 price objective on the stock...
MarketBeat·1mo ago
News Placeholder
Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire·2mo ago
News Placeholder
Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 235.81%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 235.8% in Contineum Therapeutics, Inc. (CTNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·4mo ago
<
...
1
>

Latest CTNM News

View

Advertisement|Remove ads.

Advertisement|Remove ads.